226 related articles for article (PubMed ID: 9443307)
1. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
Bellanti JA; Zeligs BJ; Kulczycki LL
Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
[No Abstract] [Full Text] [Related]
2. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
Bauernfeind A; Przyklenk B
Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
[No Abstract] [Full Text] [Related]
3. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.
Döring G
Int J Med Microbiol; 2010 Dec; 300(8):573-7. PubMed ID: 20940108
[TBL] [Abstract][Full Text] [Related]
4. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa. Vaccines and immunotherapy.
Pennington JE
Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB
FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219
[TBL] [Abstract][Full Text] [Related]
7. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
8. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice.
Lieberman MM; Ayala E
J Immunol; 1983 Jul; 131(1):1-3. PubMed ID: 6408166
[No Abstract] [Full Text] [Related]
9. [Infections in minks caused by Pseudomonas aeruginosa. Infection and vaccination trials].
Karlsson KA; Kull KE; Svanholm R
Nord Vet Med; 1971; 23(7):345-51. PubMed ID: 5004400
[No Abstract] [Full Text] [Related]
10. Active immunization of burned patients with a new multivalent Staphylococcus-Pseudomonas vaccine.
Sachs A
Prog Immunobiol Stand; 1971; 5():428-32. PubMed ID: 4633971
[No Abstract] [Full Text] [Related]
11. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
[No Abstract] [Full Text] [Related]
12. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.
Lang AB; Rüdeberg A; Schöni MH; Que JU; Fürer E; Schaad UB
Pediatr Infect Dis J; 2004 Jun; 23(6):504-10. PubMed ID: 15194830
[TBL] [Abstract][Full Text] [Related]
13. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.
Cryz SJ; Wedgwood J; Lang AB; Ruedeberg A; Que JU; Fürer E; Schaad UB
J Infect Dis; 1994 May; 169(5):1159-62. PubMed ID: 8169414
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
[No Abstract] [Full Text] [Related]
15. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.
Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G
Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185
[TBL] [Abstract][Full Text] [Related]
16. [Pseudomonas aeruginosa preparations for active immunization].
Nazarchuk LV
Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
[No Abstract] [Full Text] [Related]
17. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
Pranter W; Staerk J; Zellner R; Zwisler O
Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
[No Abstract] [Full Text] [Related]
18. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results.
Langford DT; Hiller J
Arch Dis Child; 1984 Dec; 59(12):1131-4. PubMed ID: 6441523
[TBL] [Abstract][Full Text] [Related]
19. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
[No Abstract] [Full Text] [Related]
20. Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
Beckmann C; Brittnacher M; Ernst R; Mayer-Hamblett N; Miller SI; Burns JL
Infect Immun; 2005 Jan; 73(1):444-52. PubMed ID: 15618183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
